Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Impact of Predominant Peripheral Lesions on Retinal Microvasculature and Risk of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy
Author Affiliations & Notes
  • Ioanna Ploumi
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Jenny Gan
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Xinyi Ding
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Francesco Romano
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Katherine M Overbey
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Mauricio De Jesus Garcia
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Itika Garg
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Filippos Vingopoulos
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Matthew Finn
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Peyman Razavi
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Jocelyn Rodriguez
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Cade F Bennett
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Nimesh Arvind Patel
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Deeba Husain
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Demetrios G. Vavvas
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • John B Miller
    Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, Massachusetts, United States
    Retina Service, Massachusetts Eye and Ear Department of Ophthalmology, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Ioanna Ploumi None; Jenny Gan None; Xinyi Ding None; Francesco Romano None; Katherine Overbey None; Mauricio Garcia None; Itika Garg None; Filippos Vingopoulos None; Matthew Finn None; Peyman Razavi None; Jocelyn Rodriguez None; Cade Bennett None; Nimesh Patel Alimera Sciences, Alcon, Allergan, Genentech, Eyepoint, Lifesciences Guidepoint, GLG, Code C (Consultant/Contractor), Retina Innovation Fund (Massachusetts Eye and Ear, Boston, MA), Code F (Financial Support); Deeba Husain Genentech, Allergan, Novartis, Omeicos Therapeutics, Code C (Consultant/Contractor), NIH, National Eye Institute, Lions Vision Gift, Commonwealth Grant, Lions International, Syneos LLC, Macular Society, Code F (Financial Support); Demetrios Vavvas Olix Pharma, Valitor, TwentyTwenty, Sumitomo/Sunovion, Cambridge Polymer Group, Code C (Consultant/Contractor), National Eye Institute, NIH, Research to Prevent Blindness, Loefflers Family Foundation, Yeatts Family Foundation, Alcon Research Institute, Code F (Financial Support), Massachusetts Eye and Ear, Drusolv Therapeutics, Code P (Patent); John Miller Alcon, Allergan, Carl Zeiss, Sunovion, Genentech, Topcon, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5928. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ioanna Ploumi, Jenny Gan, Xinyi Ding, Francesco Romano, Katherine M Overbey, Mauricio De Jesus Garcia, Itika Garg, Filippos Vingopoulos, Matthew Finn, Peyman Razavi, Jocelyn Rodriguez, Cade F Bennett, Nimesh Arvind Patel, Deeba Husain, Demetrios G. Vavvas, John B Miller; Impact of Predominant Peripheral Lesions on Retinal Microvasculature and Risk of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5928.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the association of predominant peripheral lesions (PPLs) with retinal microvasculature on WF SS-OCTA and the risk of VH in eyes with PDR.

Methods : The cross-sectional part of this study included 111 PDR eyes of 84 patients with same-day UWF-FP (California; Optos plc., Dunfermline, UK) and WF SS-OCTA (PLEX® Elite 9000; Carl Zeiss Meditec, Dublin, CA). A subset of 101 eyes from 75 patients followed for at least 3 months were included in the prospective part of this study, where the history of complications and treatments was reviewed. UWF-FP were graded by 2 independent graders for the presence of and the number of fields with PPLs – defined as more than 50% of diabetic lesions subjectively residing in the extended field compared to the respective ETDRS field. Only 1 field with PPLs was required for the eye to be graded as having PPLs. Ischemic index (ISI) and common SS-OCTA vascular metrics were calculated on FIJI and ARI network, respectively. 6×6- and 12×12-mm retinal microvasculature alterations were compared between eyes with and without PPLs utilizing the Mann-Whitney U test. The association between the presence and extent of PPLs and the development of VH was evaluated using generalized estimating equations and multilevel Cox mixed-effects regressions

Results : PPLs were present in 36 out of 111 eyes (32.4%). OCTA parameters, including ISI, vessel density and vessel skeletonized density did not show significant differences in groups with or without PPLs. Over a period of 18.1±10.2 months, 34 VH events occurred in 23 eyes – 14 having a history of VH (recurrent VH) and 9 having no VH history (new VH). There was an association between the presence of PPLs and the development of new VH (p=0.04), but not for recurrent VH. The number of peripheral fields with PPLs was a significant predictor for the new development of VH, after adjusting for age, DM duration and prior anti-VEGF as well as PRP (HR= 1.92, p=0.03).

Conclusions : While 6x6- and 12x12-mm OCTA metrics in eyes with or without PPLs are comparable, the presence and extent of PPLs are associated with the new development of VH. Given the advancement of UWF imaging technologies, the development of a new DR grading scheme to account for PPLs may enhance our ability to predict the risk of VH in patients with PDR.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

(A) Eye with PPLs (B) Eye without PPLs. Blue arrows indicate DBH

(A) Eye with PPLs (B) Eye without PPLs. Blue arrows indicate DBH

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×